… [ 13 ] In fact, studies in humans and experimental models demonstrated an activation of the
… microangiopathy (TMA), particularly atypical hemolytic uremic syndrome (aHUS). [ 13 ] TMA …

… atypical forms of hemolytic uremic syndrome (HUS). The key role of the complement system
is well known in TTP and atypical … The achievement of an organizational model is crucial to …

… macular degeneration (AMD) and atypical hemolytic uremic syndrome (aHUS). Genetic …
20 are likely to affect FI function, and that monitoring iC3b in a degradation assay is a useful …

… been developed as potential treatments for complement-mediated diseases (19) and efficiently
inhibited activation of the alternative pathway in vitro as well as in animal models (19, 20)…

… monitoring eculizumab discontinuation in Dutch aHUS patients after three months of
therapy. … were studied: (1) Akita+/- Ren+/- mice (a murine model of diabetes and renin-mediated …

… drug monitoring of eculizumab in atypical haemolytic–uraemic syndrome patients. … A
population PK model was developed from these data in order to: (i) describe the relationship …

… in the treatment of atypical hemolytic uremic syndrome (HUS). … Eculizumab efficacy was
monitored using serum hemolytic … the authors utilized statistical models using a propensity score …

… However, outpatient care surveillance is not ideal to treat high blood pressure … the
monitoring of kidney transplant recipients (KTR), the MACCS (Medical Assistant for Chronic Care …

… models) 64 show that the use of fresh frozen plasma can be deleterious, increasing the
presence of thrombotic complications; for this reason, antivenom is the mainstay of the treatment …

… that C5 plays a central pathogenetic role in this model, like in human aHUS. Crossing FH
R/R … This finding differs from data published earlier and regarding a different mouse model of …